Artelo Biosciences Financials - Benzinga

Artelo Biosciences Inc

ARTLNASDAQ

Trade with Public

Trade with Public

$4.65

-0.52-10.06%

Ult. Agg.: Sep 25, 2:46 PM

Panoramica Notizie Previsioni utili Eventi Obiettivi di prezzoDati finanziariSentiment Azionariato Confronta Rapporto azionario

Artelo Biosciences Financials

Artelo Biosciences (ARTL) financial statements — income, revenue, gross margin and key metrics.

Earnings & Guidance News

PRO
Artelo Biosciences Q2 EPS $(0.89) Up From $(16.83) YoY

Artelo Biosciences (NASDAQ:ARTL) reported quarterly losses of $(0.89) per share. This is a 94.71 percent increase over losses of $(16.83) per share from the same period last year.

Benzinga Newsdesk

PRO
Artelo Biosciences Q1 EPS $(4.00) Misses $(1.57) Estimate

Artelo Biosciences (NASDAQ:ARTL) reported quarterly losses of $(4.00) per share which missed the analyst consensus estimate of $(1.57) by 154.78 percent. This is a 69.14 percent increase over losses of $(12.96) per share

Benzinga Newsdesk

PRO
Artelo Biosciences Q4 EPS $1.38 Beats $(1.57) Estimate

Artelo Biosciences (NASDAQ:ARTL) reported quarterly earnings of $1.38 per share which beat the analyst consensus estimate of $(1.57) by 187.9 percent. This is a 119.66 percent increase over losses of $(7.02) per share

Benzinga Newsdesk

PRO
Artelo Biosciences Q3 EPS $(3.97) Misses $(0.82) Estimate

Artelo Biosciences (NASDAQ:ARTL) reported quarterly losses of $(3.97) per share which missed the analyst consensus estimate of $(0.82) by 384.15 percent. This is a 89.05 percent decrease over losses of $(2.10) per share

Benzinga Newsdesk

Nasdaq Gains Over 100 Points; Science Applications Shares Fall After Q2 Results

Avi Kapoor

PRO
Artelo Biosciences Q2 EPS $(5.61) Misses $(4.19) Estimate

Artelo Biosciences (NASDAQ:ARTL) reported quarterly losses of $(5.61) per share which missed the analyst consensus estimate of $(4.19) by 33.89 percent. This is a 24.67 percent decrease over losses of $(4.50) per share

Benzinga Newsdesk

© 2026 Benzinga | All Rights Reserved